Affimed N.V.: Modular ROCK™platform enabling multi-specific NK / T-cell bi-and tri-specific Abs. Aug 2018 deal with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics through application of ROCK platform. Lead NK cell engager AFM13 (CD30/CD16A) in Ph1b combo w/ Keytruda in Hodgkins and Ph2a (mono) in CD30(+) lymphoma including TCL. T-cell engager AFM11 (CD19/CD3) in 2 dose escalation studies in ALL and NHL.
Based in...
Europe, USA
Clinical Stage
Phase l or ll
Disease Space
Hematology, Immuno-Oncology, Oncology
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Platform Technology
Im Neuenheimer Feld 582
Heidelberg, 69120

Company Participants at Affimed KOL Event Dec 7

  • Adi Hoess, Ph.D., Chief Executive Officer
  • Florian Fischer, Ph.D., MBA, Chief Financial Officer
  • Gregory Gin, Head of Investor Relations

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.